Insmed to Present New Data Across Its Respiratory Portfolio at CHEST 2026 and IDWeek 2026
—Three Late-Breaking Abstracts at CHEST 2026 Deepen Understanding of the Potential of Treprostinil Palmitil Inhalation Powder (TPIP) Across Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)— —New Analysis From the Phase 3...
Covered in this story
What has happened since
- Parker Hannifin is down 7.9% since this was published, 9 days ago.
- Associated Bancorp is up 6.6% since this was published, 9 days ago.
- Insmed is down 4.5% since this was published, 9 days ago.
Price move measured from the close nearest publication to the latest quote.
Analyst targets on Parker Hannifin
- Stifel: $962 → $1.07k by Oct 2027 · Hold via Investing.com
- TD Cowen: $954 → $950 by Oct 2027 · Hold via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $PH yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Parker Hannifin →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.